Seegene and Springer Nature announce strategic partnership
Thursday, May 30, 2024
Seegene, South Korea's leading molecular diagnostics (MDx) company, announced on May 16 that it has signed a strategic alliance agreement with Springer Nature, the publisher of the prestigious scientific journal Nature.
Shared values, such as Springer Nature's goal to advance research and Seegene's vision for a "world without disease", form the basis for a successful partnership.
Under the new partnership, the two companies will leverage their combined expertise and knowledge to help researchers around the world accelerate the development of PCR diagnostic tests for important but distinct disease areas.
PCR molecular diagnostics companies develop only a small number of diagnostic products each year. By connecting with Springer Nature's network, the two companies will support scientists and experts in various fields worldwide with funding and technology, significantly expanding the range and potential of diagnostic products. This initiative, led by the senior management of both companies, builds on the success of the Open Innovation program that the two companies launched in 2023 with the aim of developing innovative diagnostic products with the participation of the scientific community.
Both companies will expand their collaboration through the SG OneSystem TM by identifying and nurturing potential partners and jointly hosting annual symposiums, starting with a joint declaration this year.
"We are very pleased to deepen our strategic relationship with Springer Nature, a leader in the global scientific community," said Dr. Jong-Yoon Chun , CEO and founder of Seegene. "Together, we will work to drive the success of the SG OneSystem TM business and realize a 'world without disease'."
"Springer Nature welcomes Seegene's efforts to democratize early diagnosis of various diseases to enable timely treatment," said Frank Vrancken Peeters, Managing Director of Springer Nature.
"This ambitious goal can only be achieved through collaboration. As a trusted partner of the research community, Springer Nature will help build a global network of experts who can use Seegene's technology to accelerate the development of new tests for a wide range of diseases."
Seegene and Springer Nature have received strong interest from the global scientific community for the first Open Innovation Program launched in 2023. The program, which includes 15 projects, received a total of 281 applications from 47 countries, resulting in a competitive ratio of 11 to 1 to select 26 applicants. The two companies have recognized the potential of sharing technologies and aim to advance the commercialization of know-how and knowledge in various fields. This year, the program is being implemented for the second time and deviates from the 2023 model of predefined product development. Instead, the 2024 program will adopt a more open format that allows applicants to submit proposals for any product development.
"We have high expectations that the Open Innovation Program will contribute to the democratization of molecular PCR diagnostics," said Marc Spenlé, Chief Operating Officer at Springer Nature. "Together with Seegene, we will create an ecosystem that promotes and accelerates the development of new tests for currently unmet needs."
Information about Seegene
Seegene has 23 years of experience in the research and development, manufacturing and operation of quantitative syndromic PCR technologies, which was particularly evident during the COVID-19 pandemic when the company delivered more than 340 million COVID-19 tests to more than 100 countries worldwide. The core element of Seegene's unique syndromic PCR technology is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single PCR approach and provide quantitative information on the infectivity profile that correlates with disease severity.
Information about Springer Nature
For over 180 years, Springer Nature has advanced research by providing the best possible service to the entire research community. They help researchers discover new ideas and ensure that all research published by Springer is meaningful, stands up to objective scrutiny, reaches all relevant audiences in the best possible form, and can be discovered, accessed, used, reused and shared. They support librarians and institutions with innovations in technology and data, and provide high-quality publishing support to societies.
As a scientific publisher, Springer Nature includes trusted brands such as Springer, Nature Portfolio, BMC, Palgrave Macmillan and Scientific American.
For more information, visit springernature.com and @SpringerNature .
ADDITIONAL INFORMATION
SG OneSystemTM
SG OneSystem TM is Seegene's global strategy to share its PCR molecular diagnostics technology and know-how acquired over more than 20 years with leading companies worldwide to form a global consortium to expand the development pipeline of PCR products. In addition, Seegene aims to leverage the collective expertise and knowledge of the global scientific community to drive innovation in the field of diagnostics. Through these joint efforts, commercialization of expertise and knowledge, and development of diagnostic products tailored to the needs of the local market, SG OneSystem TM aims to democratize early access to PCR testing and ultimately contribute to the realization of a "world free of disease."
In January 2024, Seegene entered into a strategic partnership with Microsoft to strengthen the Seegene Digitalized Development System (SGDDS) using Microsoft's technology, including plans for the future use of artificial intelligence (AI). Seegene's collaboration with Microsoft and Springer Nature will advance SG OneSystem TM 's business . The three companies plan to hold an information event to kick off the collaboration this year.
Open Innovation Programme (OIP)
The Open Innovation Program (OIP) is a global PCR reagent development project jointly hosted by Seegene and Springer Nature. Launched in September 2023 , the inaugural program invited scientists and experts from across the community to apply to conduct 15 designated research projects to develop reagents for Seegene's syndromic qPCR diagnostics.
The Open Innovation Program is part of Seegene's technology sharing project, SG OneSystem TM , which aims to "realize a world free of all diseases, with the goal of developing products that pool the knowledge and experience of scientists and experts worldwide."
Seegene Digitized Development System (SGDDS)
The Seegene Digitalized Development System (SGDDS) is a system that enables standardized and automated development of diagnostic kits. It is embedded with Seegene's technologies and product know-how and provides support to scientists to easily develop syndromic PCR products even if they have limited development experience.
Source: prnewswire.com